Go Back This article was viewed 95 times

Review Article


Circulating tumor cells in breast cancer

Akhil JainMoushumi SuryavanshiUllas BatraPankaj GoyalDinesh Doval
Departments of Medical Oncology1Consultant, Center for Molecular Diagnostics & Cell Biology, 2Department of Medical Oncology & Research, Rajiv Gandhi Cancer Institute & Research Centre, NewDelhi, India, 
Corresponding Author:

Akhil Jain

Departments of Medical Oncology, Center for Molecular Diagnostics & Cell Biology, Rajiv Gandhi Cancer Institute & Research Centre, NewDelhi, India
E-mail: drakhiljain17@gmail.com

Corresponding Author:

Akhil Jain

Departments of Medical Oncology, Center for Molecular Diagnostics & Cell Biology, Rajiv Gandhi Cancer Institute & Research Centre, NewDelhi, India
E-mail: drakhiljain17@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20170052

ABSTRACT


Breast cancer is a heterogeneous disease. Liquid biopsy is a novel diagnostic tool and may provide answers to many questions related to unevenness in prognosis and ultimate outcome. Different technologies for CTC isolation, enrichment, detection, and characterization are under evaluation. Various clinical trials and meta-analysis have been conducted to define the role of CTC in early and metastatic breast cancer. CTCs are superior to other serum markers for prognostication. Their role as predictive marker remains elusive.
Keywords: Circulating tumor cells, Early breast cancer, Metastatic breast cancer, Liquid biopsy